门冬酰胺酶相关儿童急性胰腺炎诊治研究进展

Progress of diagnosis and treatment of asparaginase associated pancreatitis in children

门冬酰胺酶（ASP）是儿童急性淋巴细胞白血病和非霍奇金淋巴瘤联合化疗方案中的关键药物之～。ASP相关急性胰腺炎（AAP）是ASP的主要严重不良反应。现通过复习有关儿童AAP的近年国内外文献和我国《培门冬酶治疗急性淋巴细胞白血病和恶性淋巴瘤的专家共识》，以及对网络收集的历年来我国儿童AAP报道资料进行归纳与统计分析，参照国际AAP诊断标准，提出儿童AAP流行病学、临床表现、早期诊断和有效治疗要点，以及左旋门冬酰胺酶和培门冬酶的AAP临床对比。全文资料数据详尽，分析归纳依据充分，相关经验的临床可操作性强，对临床有效诊治儿童AAP具有较大的参考价值。

Asparaginase（ASP） is an important drug in the treatment of childhood acute lymphoblastic leukemia and non - Hodgkin lymphoma. Asparaginase associated pancreatitis （AAP） is the main treatment - adverse events of asparaginase. After reviewing the recent foreign literatures about AAP and the Chinese expert about polyethylene glycol conjugated asparaginase （ PEG - ASP） in the treatment of acute lymphoblastic leukemia and malignant lymphoma with asparaginase, conclude and analysis the data about childhood AAP and show the epidemiology, clinical features, early diagnosis and effective treatment of children with AAP. Make clinical compare of L - asparaginase and PEG - ASP. Based on the full grip of the relevant data, analyziug, introducing and integrating ,this may be helpful to the diagnosis and treatment of childhood AAP.